| Company | Purpose | Anonymous Data Shared | When collaboration Happened |
| Epigenomics | Validation of a new technique for improved sensitivity of lung cancer diagnosis in bronchial lavage samples | None – data analysed in-house and results shared. | 2010 – 2012 |
| Oxgford Gene Technologies | Investigating our ability to find useful DNA mutations routinely collected tumour histology samples (e.g. that might help target treatment or aid prognosis). | None – data analysed in-house and results shared. | 2013 – 2015 |
| Inivata Ltd | Investigating new technology to find useful DNA mutations in blood samples | Cancer diagnosis (type and stage) | 2015 – 2017 |
| Biocrates life sciences ag | Investigating the potential new technologies for cancer detection based on metabolites in blood | Risk profile and disease status | 2016 – 2020 |
| Janssen Pharmaceuticals | Grant support for lung cancer research collaboration on early detection and prevention Risk profile and disease status | None – data analysed in-house and results shared. | 2018- 2023 |
| Roche Diagnostics | Grant support to investigate protein biomarkers for improved diagnosis of lung cancer | None – data analysed in-house and results shared. | 2020 – 2022 |
| Company A* | Collaboration investigating possible resistance to lung cancer and COPD | Ages at lung cancer and/or COPD, smoking duration/status, sex and outcome | 2020 – 2026 |
| Company T* | Feasibility study for use of samples in epigenetics. | Age at lung cancer, histology, stage, sex and mutations | 2024 – 2025 |
| Elypta AB | Validation of GAGome risk marker for cancer early diagnosis. | Sex, age at sample, cancer diagnosis, stage, histology, risk factors, comorbidities, outcome. | 2023 – 2026 |